Literature DB >> 21688175

Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein.

Irene F Gazi1, Fotini A Apostolou, Evangelos N Liberopoulos, Theodosios D Filippatos, Constantinos C Tellis, Moses S Elisaf, Alexandros D Tselepis.   

Abstract

The objective of the present study was to evaluate the effects of acute infection with Leptospira interrogans on lipids, lipoproteins and associated enzymes. Fasting serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoproteins (apo) A-Ι, B, E, C-II, C-III and lipoprotein (a) [Lp(a)] were determined in patients with Leptospirosis on diagnosis and 4 months after recovery as well as in age- and sex-matched controls. Activities of cholesteryl-ester transfer protein (CETP) and lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) as well as paraoxonase 1 (PON1) hydrolysing activity and levels of cytokines were determined. LDL subclass analysis was performed with Lipoprint LDL System. Eleven patients (10 men, mean age 49.5 ± 8.4 years) and 11 controls were included. TC, HDL-C, LDL-C, apoA-I, apoB and Lp(a) levels were lower at baseline, whereas TG and apoE levels were elevated compared with 4 months later. At baseline, higher levels of cytokines and cholesterol concentration of small dense LDL particles (sdLDL-C) were noticed, whereas LDL particle size was lower compared with follow-up. Activities of plasma Lp-PLA(2) and HDL-associated Lp-PLA(2) were lower at baseline compared with post treatment values, whereas PON1 activity was similar at baseline and 4 months later. 4 months after recovery, the levels of all lipid parameters evaluated did not differ compared with controls, except for HDL-C which remained lower. PON1 activity both at baseline and 4 months later was lower in patients compared with controls. Leptospirosis is associated with atherogenic changes of lipids, lipoproteins and associated enzymes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688175     DOI: 10.1007/s11745-011-3580-y

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  44 in total

1.  Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection.

Authors:  Sandra Parra; Carlos Alonso-Villaverde; Blai Coll; Natàlia Ferré; Judit Marsillach; Gerard Aragonès; Michael Mackness; Bharti Mackness; Lluis Masana; Jorge Joven; Jordi Camps
Journal:  Atherosclerosis       Date:  2006-08-30       Impact factor: 5.162

2.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats.

Authors:  K M Howard; M S Olson
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

Review 4.  Nutrition disorders during acute renal failure and renal replacement therapy.

Authors:  Patricia Wiesen; Lionel Van Overmeire; Pierre Delanaye; Bernard Dubois; Jean-Charles Preiser
Journal:  JPEN J Parenter Enteral Nutr       Date:  2011-03       Impact factor: 4.016

5.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements.

Authors:  H Gierens; M Nauck; M Roth; R Schinker; C Schürmann; H Scharnagl; G Neuhaus; H Wieland; W März
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-07       Impact factor: 8.311

7.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

Authors:  Irene Gazi; Evangelia S Lourida; Theodosios Filippatos; Vasilis Tsimihodimos; Moses Elisaf; Alexandros D Tselepis
Journal:  Clin Chem       Date:  2005-10-13       Impact factor: 8.327

8.  Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis.

Authors:  R M Graham; C J Stephens; W Silvester; L L Leong; M J Sturm; R R Taylor
Journal:  Crit Care Med       Date:  1994-02       Impact factor: 7.598

Review 9.  Leptospirosis: an emerging global public health problem.

Authors:  P Vijayachari; A P Sugunan; A N Shriram
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

10.  Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis.

Authors:  S Endo; K Inada; H Yamashita; T Takakuwa; H Nakae; T Kasai; M Kikuchi; M Ogawa; K Uchida; M Yoshida
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1994-03
View more
  10 in total

Review 1.  Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise.

Authors:  G Liamis; T D Filippatos; A Liontos; M S Elisaf
Journal:  Hepatol Int       Date:  2016-06-21       Impact factor: 6.047

Review 2.  Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Authors:  Sebastian Filippas-Ntekouan; Evangelos Liberopoulos; Moses Elisaf
Journal:  Infection       Date:  2017-05-08       Impact factor: 3.553

Review 3.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

4.  High density lipoprotein and cardiovascular diseases.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-07-26

5.  Leptospiral LruA is required for virulence and modulates an interaction with mammalian apolipoprotein AI.

Authors:  Kunkun Zhang; Gerald L Murray; Torsten Seemann; Amporn Srikram; Thanatchaporn Bartpho; Rasana W Sermswan; Ben Adler; David E Hoke
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

6.  The relationship of oleic acid/albumin molar ratio and clinical outcomes in leptospirosis.

Authors:  Caroline Azevedo Martins; Maria Conceição B Dos Santos; Cassiano Felippe Gonçalves-de-Albuquerque; Hugo Caire Castro-Faria-Neto; Mauro Velho Castro-Faria; Patricia Burth; Mauricio Younes-Ibrahim
Journal:  Heliyon       Date:  2021-03-08

Review 7.  Persistence of Lipoproteins and Cholesterol Alterations after Sepsis: Implication for Atherosclerosis Progression.

Authors:  Krzysztof Laudanski
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 6.208

8.  Long-Term Abnormalities of Lipid Profile After a Single Episode of Sepsis.

Authors:  Nicholas Felici; Da Liu; Josh Maret; Mariana Restrepo; Yuliya Borovskiy; Jihane Hajj; Wesley Chung; Krzysztof Laudanski
Journal:  Front Cardiovasc Med       Date:  2021-11-15

9.  Integrated Metabolomic and Transcriptomic Analysis of Acute Kidney Injury Caused by Leptospira Infection.

Authors:  Kuan-Hsing Chen; Li-Fang Chou; Cheng-Chieh Hung; Hsiang-Yu Tang; Mei-Ling Cheng; Huang-Yu Yang; Hsiang-Hao Hsu; Ya-Chung Tian; Chih-Wei Yang
Journal:  Pathogens       Date:  2022-07-04

10.  Lipidomic analysis of immune activation in equine leptospirosis and Leptospira-vaccinated horses.

Authors:  Paul L Wood; Margaret Steinman; Erdal Erol; Craig Carter; Undine Christmann; Ashutosh Verma
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.